reproxalap

reproxalap: developed by 1 company · 3 FDA decisions. Updated within the last hour.

Development Pipeline (1)

FDA Decisions

FDA_MeetingFDA has extended the PDUFA date for topical ocular reproxalap for treatment of signs and symptoms of dry eye disease.(ALDX)
PDUFAthe signs and symptoms of dry eye disease(ALDX)
CRLdry eye disease(ALDX)

Frequently asked questions

Who is developing reproxalap?

reproxalap is being developed by Aldeyra Therapeutics, Inc..

What is reproxalap's latest FDA decision?

The most recent tracked FDA decision for reproxalap is FDA_Meeting for FDA has extended the PDUFA date for topical ocular reproxalap for treatment of signs and symptoms of dry eye disease..

Get deeper analysis on reproxalap

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    reproxalap — Drug Pipeline, Trials & FDA Status | BioSniper